USPTO 2015–2025 USPTO PatentsView US Corporation

E.I. DU Pont DE Nemours AND Company

USPTO PatentsView assignee record - 882 granted patents across 184 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

RSS updates for this company

The verdict

According to USPTO PatentsView, E.i. ranks #511 of 49,997 tracked US assignees by granted-patent volume, with 882 patents across 184 technology areas.

#511
of 49,997 US assignees by volume
Top 5%
by Innovation Score (57.8/100)
13.6
avg claims per patent
-91%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R511 · US Corporation #511 · 882 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MID 882 grants
  • TOP-DECILE #511/49,997
  • PHOTO-FINISH Furukawa Electric
  • CPC-WIDE C12N · 184 areas
  • INNOV-PAR 57.8/100
  • CLAIMS-RICH 13.6 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -91% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Furukawa Electric Co., Ltd. (±1 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around E.i.

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows E.i.'s Innovation Score is 57.8/100 (top 5% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

How E.i.'s grant cadence moved

Between 2020–2024, E.I. DU Pont DE Nemours AND Company received 74 grants versus 807 in 2015–2019 (-91% equal-window velocity, below median growth). Across complete PatentsView years, output peaked in 2015 at 297 grants and bottomed in 2024 at 1. Lead class C12N accounts for 23.5% of the portfolio across 184 subclasses. Volume neighbours: Societe des Produits Nestle S.A. (#507) and Amgen Inc. (#515).

E.i.'s three-year grant acceleration

From 2019–2021 to 2022–2024, E.I. DU Pont DE Nemours AND Company moved from 121 to 22 grants (0.18x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #3,115. See the growth leaderboard.

Who files at EI's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows E.I. holds 882 patents at rank #511, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near EI

By rank, the assignees closest to #511 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in EI's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for EI, neither rank-band nor same-CPC leaders (those blocks stay above).

E.i.'s Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

58 Top 5% higher than 95% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0100200300400 20152016201720182019202020212022202320242025 1
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
E.I. DU Pont DE Nemours AND Company patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 297 33.7%
2016 182 20.6%
2017 151 17.1%
2018 108 12.2%
2019 69 7.8%
2020 31 3.5%
2021 21 2.4%
2022 16 1.8%
2023 5 0.6%
2024 1 0.1%
2025partial year 1 0.1%

Which technologies does E.I. DU Pont DE Nemours AND Company patent most?

Top 15 of 184 technology areas

Where it ranks

Overall rank by patents

#511

of 49,997 tracked assignees

Innovation Score

57.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

E.I. DU Pont DE Nemours AND Company's patent record in context - here's where to go next.

  • E.I. DU Pont DE Nemours AND Company's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 23.5% of its portfolio - see every assignee active in that class. Explore C12N
  • Ranked #511 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare E.I. DU Pont DE Nemours AND Company against Societe des Produits Nestle S.A., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 57.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.